HCA
XENE icon

Harbor Capital Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Harbor Capital Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,053
Closed -$451K – 1510
2025
Q4 		$451K Sell
10,053
-1,165
-10% -$48.9K 0.04% 516
2025
Q3 		$450K Sell
11,218
-18,818
-63% -$663K 0.04% 507
2025
Q2 		$940K Sell
30,036
-26,555
-47% -$866K 0.04% 445
2025
Q1 		$1.9M Buy
56,591
+6,773
+14% +$257K 0.09% 296
2024
Q4 		$1.95M Buy
49,818
+1,755
+4% +$72.6K 0.09% 297
2024
Q3 		$1.89M Buy
48,063
+23,947
+99% +$966K 0.08% 313
2024
Q2 		$940K Buy
24,116
+20,891
+648% +$835K 0.07% 370
2024
Q1 		$139K Buy
+3,225
New +$148K 0.02% 683
2023
Q3 		– Sell
-547
Closed -$21.1K – 657
2023
Q2 		$21.1K Buy
+547
New +$21.7K ﹤0.01% 590

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Harbor Capital Advisors's XENE Position: Q1 2026 in Review

Harbor Capital Advisors sold out of Xenon Pharmaceuticals (XENE) in Q1 2026, closing a stake of 10,053 shares — an estimated $451K sold.

Harbor Capital Advisors first reported a position in XENE in Q2 2023 and held it in 9 quarters. The position peaked at $1.95M in Q4 2024. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Harbor Capital Advisors reported no remaining Xenon Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Harbor Capital Advisors sold 10,053 Xenon Pharmaceuticals shares in Q1 2026, an estimated $451K.
  • Harbor Capital Advisors first reported a position in Xenon Pharmaceuticals in Q2 2023 and held it in 9 quarters.
  • Harbor Capital Advisors's Xenon Pharmaceuticals position peaked at $1.95M in Q4 2024.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Harbor Capital Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.